The value of investments can fall as well as rise. Investors may get back less than they invested. Past performance is not a reliable indicator of future results. Capital at Risk.
CORPORATE
BROKING
Oberon Capital has a highly experienced team, providing full market access and fundraising capabilities to clients. At the heart of our offering is the access to capital and providing services that are 100% aligned with achieving your company’s goals.
Services
Recent Transactions
Research & Events Portal
APPROACH
Personal Relationships – Strong relationships are at the heart of our success, and we dedicate a lot of time to building them. We will actively engage and work closely with clients to ensure that we fully understand your aims and motivations. Trusted relationships with a diverse network of investors allow us to efficiently source funding when needed.
Expertise and Enthusiasm – Our team is highly experienced in their respective disciplines, having come to Oberon with successful personal track records. We have come together as Oberon Capital to create a division that combines these skills within an entrepreneurial environment. This provides an opportunity to build a firm that addresses the challenges of a rapidly changing market. This sense of ownership translates into the enthusiasm that we have to build a successful business, built on delivering successful outcomes for clients.
Your Success is our Success – Our interests are fully aligned with yours. We only succeed if you succeed, and we work tirelessly to ensure you achieve your goals.
NICK LOVERING
HEAD OF OBERON CAPITAL
We invest our time in relationships. Not just our relationship with you, we make sure we know the people behind the companies we invest in.
AIMEE MCCUSKER
DIRECTOR
OUR SERVICES
1. ACCESS TO CAPITAL
We act as broker for companies on all UK markets, whether the LSE, AIM or Aquis. Collectively, the team has helped more than a hundred companies through IPOs, across all sectors and on each UK market. We have a proven track record of being able to source capital and of advising listed companies on successful funding rounds. We are also a leading Aquis Corporate Adviser.
We have launched IPOs even in challenging market conditions.
We also offer fundraising in private markets, to a principally institutional audience.
2. EQUITY RESEARCH
Equity research can be of very significant value, but it is not needed all the time or by everyone. Our clients have access to our panel of highly experienced and well-respected equity analysts, who work with us on a consultancy basis. This makes our model much more flexible and affordable for you. Our research is sent to a wide population of institutional clients and via the Research Tree portal.
3. Corporate Broking and Investor Relations
We provide high-quality, bespoke Corporate Broking services as each of our clients have a different set of requirements. Our focus is on the personal relationships, which sees us actively engage with our clients’ senior team members. We keep clients updated on market trends, news and trading so that when you come to launch a transaction, you are fully informed.
Over the years, we have built up long-standing and trusted relationships with a multitude of investors. We will succeed if our clients succeed, and we align our services precisely to this mission. This has helped us to establish a track record of successful outcomes for our clients. We offer a market leading Investor Relations service, which leverages the latest digital and online tools to disseminate investor messaging and ensure maximum exposure to the widest possible investor audience.
MIKE SEABROOK
FOUNDER & HEAD OF SALES
4. FINANCIAL ADVISORY / M&A
Our team has extensive experience in advising on corporate transactions for both public and private companies and expertise in matters relating to the UK Takeover Code, on both the buy and sell side. We can offer you high-quality technical expertise, combined with commercially focused advice and a collaborative approach with other advisers.
RECENT TRANSACTIONS
Below are some of our recent transactions.
GELION
£10m Fundraise, AIM, October 2025
£2.6m Fundraise, AIM, April 2025
£1.6m Fundraise, AIM, December 2024
Acted as joint broker & joint bookrunner to Gelion plc. Gelion is at the forefront of developing Sulfur Batteries, which have significant advantages of Lithium-Ion batteries, including double the gravimetric density, lower manufacturing costs, a lack of toxic solvents or metals, improved safety characteristics and a 30% reduction in carbon footprint.
EDX MEDICAL
£4m Fundraise, AQSE ; October 2025
£3m Fundraise, AQSE, March 2025
£5.7m Fundraise, AQSE, February 2024
Acted as corporate adviser and broker to EDX Medical Group plc, on two fundraises to support the acceleration of the development of products to help meet global demand from healthcare providers delivering personalised treatments.
TEAM PLC
£1.1m Fundaise, AIM, December 2024
£1.1m Fundraise, AIM, March 2024
Acted as corporate broker to TEAM plc, on its £1.1m fundraise. The raise will go towards financing of acquisitions and deferred consideration, as well as providing cash for working capital and general corporate purposes.
ZINNWALD LITHIUM
£3.1m Fundraise, AIM, June 2025
£18.5m Fundraise, AIM, March 2023
Acted as joint broker to Zinnwald, which is a lithium development company focused on becoming an important supplier to Europe’s fast- growing battery sector. The Company owns the integrated Zinnwald Lithium Project in Germany, a development-stage project with attractive economics and approved mining licence.
OBERON
£1.5m Fundraise, AQSE, September 2025
£2.5m Fundraise, AQSE, February 2025
£2.5m Fundraise, AQSE, August 2024
£2.5m Fundraise, AQSE, September 2023
Oberon Capital has acted as corporate broker to Oberon Investments, on a number of fundraises. The fundraises provide Oberon with additional resources to continue growth and help secure new investment teams and supporting the launch of innovative new products and services.
RENALYTIX
£7m Fundraise, AIM, September 2025
£11.8m Fundraise, AIM, October 2024
Acted as as sole bookrunner to Renalytix plc. This fundraising will support Renalytix at a crucial and very exciting time. Its KidneyIntelX™ product is the only kidney prognostic test that is FDA approved and has full Medicare reimbursement granted, at $950 per test.
LIGHT SCIENCE TECHNOLOGIES
£1.5m Fundraise, AIM, April 2023
Acted as corporate broker to Light Science Technologies Holdings plc, which comprises of three divisions: controlled environment agriculture; contract electronics manufacturing and passive fire protection.
TIME TO ACT PLC
IPO, AQSE, May 2024
Acted as corporate broker to Time To ACT plc, on its Aquis IPO. TTA is an engineering business focused on technology for the energy transition sector.
INTELLIAM AI
£20m IPO, AQSE, July 2024
Acted as corporate adviser and broker to IntelliAM AI plc, on its Aquis IPO. IntelliAM is a technology and consultancy company, which uses machine learning and data analytics to drive efficiency and to improve the performance of clients’ manufacturing assets and machinery.
ONDINE BIOMEDICAL
£10.8m Fundraise, AIM, November 2024
Acted as joint bookrunner to Ondine BioMedical Inc, £9 million by way of a successful placing. The primary objective of the Fundraising is to provide the Company with sufficient capital to conduct the U.S. Phase 3 clinical study for its nasal photodisinfection system (branded as Steriwave® outside the U.S.).
GENINCODE
£4m Fundraise, AIM, February 2025
Acted as joint bookrunner to GENinCode on its £4m Fundraise. The raise will be used to fund the completion of the Company’s US regulatory and reimbursement program whilst driving commercialisation in the US, expanding its activities in the UK and Europe whilst positioning the Company on a pathway to breakeven/profitability over the medium term.
COINSILIUM GROUP
£1.25m Fundraise, AQSE, May 2025
Acted as Joint Broker to Coinsilium Group Limited. The net proceeds of the Placing will be deployed to further the development of Forza (Gibraltar) Limited, the Company’s wholly-owned vehicle dedicated to Bitcoin-based treasury activities, to fund further investments and general working capital.
VERICI DX PLC
£5.92m Fundraise, AIM, July 2025
Acted as joint broker to Verici Dx plc, which is a a developer of advanced clinical diagnostics for organ transplant. The funds are to accelerate commercial growth and support the scale up of revenues from their lead product, Tutivia.